Metabolic syndrome – Evidence-based strategies for patient optimization

Reyes, Shuhan; Pak, Taylor; Moon, Tiffany S.

doi:10.1016/j.bpa.2020.04.002

Cited by 4 publications

(2 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ER -endoplasmic reticulum FA -fatty acid HDL -high density lipoproteins IDF -International Diabetes Federation MS -metabolic syndrome NAFLD -non-alcoholic fatty liver disease TC -total cholesterol TG -triglycerides WHO -World Health Organization A s a critical risk factor for the development of cardiovascular diseases, the problem of metabolic syndrome (MS) is one of the highest priorities and relevant in modern fundamental and clinical medicine [1]. This is due to the fact that MS contains several metabolic, inflammatory, hormonal and vascular disorders, which significantly increase the risk of developing second-type diabetes mellitus and various cardiovascular complications [2].…”

Section: экспериментальная медицинаmentioning

confidence: 99%

Morphological changes in the liver and intestine in the experimental metabolic syndrome in rats

Petrenko¹,

Saenko²,

Khalilova³

et al. 2022

Medical news of the North Caucasus

View full text Add to dashboard Cite

Metabolic syndrome (MS) is a complex of disorders closely associated with developing the non-alcoholic fatty liver disease (NAFLD) accompanied by a violation of the intestinal microbiota. An assessment of morphological changes in the liver and intestines during the development of experimental metabolic syndrome in rats was carried out. The study was performed on 32 Wistar white rats aged 10-12 months using a 60 % fructose feeding pattern for 16 weeks as the MS model. It has been established that the fructose feeding model in rats causes the development of NAFLD with the result of a violation of the bar structure of the lobules, moderate intralobular inflammation, and the formation of hepatocellular granular dystrophy and perisinusoidal fibrosis. In the intestinal villi, destruction of apical epithelial cells and changes in cell nuclei are observed. Thus, the development of MS in rats is accompanied by the formation of signs of non-alcoholic steatohepatosis and damage to intestinal cells, which confirms the involvement of these organs as the primary target organs in MS, and contributes to the development of metabolic, dysbiotic, and inflammatory disorders.

show abstract

Section: экспериментальная медицинаmentioning

confidence: 99%

Morphological changes in the liver and intestine in the experimental metabolic syndrome in rats

Petrenko¹,

Saenko²,

Khalilova³

et al. 2022

Medical news of the North Caucasus

View full text Add to dashboard Cite

show abstract

“…Obesity is commonly associated with the development of hypertension, dyslipidemia, and insulin resistance, a cluster of conditions known as metabolic syndrome. Patients with metabolic syndrome are at risk of developing significant comorbidities including type 2 diabetes, myocardial infarction, and stroke compared with the general population [16]. Metabolic syndrome is also associated with an increased risk of adverse perioperative outcomes when compared with obese patients without metabolic syndrome, including higher infection rates, increased postoperative atelectasis, need for postoperative intensive care unit care and mechanical ventilation, longer hospital stay, and mortality [16].…”

Section: Metabolic Syndromementioning

confidence: 99%

Advanced endoscopic gastrointestinal techniques for the bariatric patient: implications for the anesthesia provider

Kim

Spiro²,

Hatzidais³

et al. 2021

Current Opinion in Anaesthesiology

View full text Add to dashboard Cite

Purpose of reviewThe incidence of obesity and the use of endoscopy have risen concurrently throughout the 21st century. Bariatric patients may present to the endoscopy suite for primary treatments as well as preoperatively and postoperatively from bariatric surgery. However, over the past 10 years, endoscopic bariatric and metabolic therapies (EBMTs) have emerged as viable alternatives to more invasive surgical approaches for weight loss. Recent findingsThe United States Food and Drug Administration (FDA) has approved several different gastric EBMTs including aspiration therapy, intragastric balloons, and endoscopic suturing. Other small intestine EBMTs including duodenal mucosal resurfacing, endoluminal magnetic partial jejunal diversion, and Duodenal-Jejunal Bypass Liner are not yet FDA approved, but are actively being investigated. SummaryObesity causes anatomic and physiologic changes to every aspect of the human body. All EBMTs have specific nuances with important implications for the anesthesiologist. By considering both patient and procedural factors, the anesthesiologist will be able to perform a safe and effective anesthetic.

show abstract

Pancreatoduodenectomy: the Metabolic Syndrome is Associated with Preventable Morbidity and Mortality

Gazivoda

Greenbaum

Beier

et al. 2022

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

Metabolic syndrome – Evidence-based strategies for patient optimization

Cited by 4 publications

References 83 publications

Morphological changes in the liver and intestine in the experimental metabolic syndrome in rats

Morphological changes in the liver and intestine in the experimental metabolic syndrome in rats

Advanced endoscopic gastrointestinal techniques for the bariatric patient: implications for the anesthesia provider

Pancreatoduodenectomy: the Metabolic Syndrome is Associated with Preventable Morbidity and Mortality

Contact Info

Product

Resources

About